Abstract
PTK787/ZK 222584 (PTK/ZK) is an oral angiogenesis inhibitor targeting vascular endothelial growth factor (VEGF) receptor tyrosine kinases, including VEGFR-1/Flt-1, VEGFR-2/KDR, VEGFR-3/Flt-4, the platelet-derived growth factor receptor tyrosine kinase and the c-kit protein tyrosine kinase. The objective of this Phase I study was to evaluate the safety, tolerability, biologic activity and pharmacologic profile of PTK/ZK administered orally, twice daily, on a continuous dosing schedule in patients with primary refractory or relapsed acute myeloid leukemia (AML), secondary AML, poor-prognosis de novo AML or advanced myelodysplastic syndrome (MDS). Acute myeloid leukemia patients for whom PTK/ZK monotherapy was ineffective could receive PTK/ZK combined with standard induction chemotherapy. Sixty-three patients received PTK/ZK at doses of 500–1000 mg orally b.i.d. Safety and pharmacokinetic data were collected. Responses were evaluated according to standard bone marrow and peripheral blood criteria. At 1000 mg b.i.d., dose-limiting toxicities of lethargy, hypertension, nausea, emesis and anorexia were observed. Other adverse events related to PTK/ZK were dizziness, weakness, fatigue, diarrhea and pruritus; these were generally mild and reversible. Pharmacokinetic data showed that steady state was reached by day 14, there was no accumulation with repeat dosing and there was no significant increase in exposure at steady state beyond the maximum tolerated dose (MTD). Complete remission was observed in five of 17 AML patients treated with PTK/ZK combined with chemotherapy.In conclusion, the MTD of PTK/ZK is 750 mg orally b.i.d. The drug is generally well tolerated and can be given in combination with chemotherapy for patients with MDS and AML.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995; 1: 27–31.
Weinstat-Saslow D, Steeg PS . Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 1994; 8: 401–407.
Liotta LA, Steep PS, Stetler-Stevenson WG . Cancer metastasis and angiogenesis: an imbalance of negative and positive regulation. Cell 1991; 64: 327–336.
Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 96: 2637–2644.
Hussong JW, Rodgers GM, Shami PJ . Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309–313.
Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240–2245.
De Bont ED, Rosati S, Jacobs S, Kamps WA, Vellenga E . Increased bone marrow vascularization in patients with acute myeloid leukemia: a possible role for vascular endothelial growth factor. Br J Haematol 2001; 113: 296–304.
Dvorak HF, Detmar M, Clafey KP . Vascular permeability factor (vascular endothelial growth factor) – an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995; 107: 233–235.
Ferrara N . The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36: 127–137.
Zhang HT, Craft P, Scott PAE . Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor in MCF-7 human breast carcinoma cells. J Nat Cancer Inst 1995; 87: 213–219.
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML et al. Failure of blood-island formation and vasculogenesis in FLK-1 deficient mice. Nature 1995; 376: 62–66.
Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435–439.
Bellamy WT, Richter L, Frutiger Y, Grogan TM . Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728–733.
Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999; 81: 1398–1401.
Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870–1875.
Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427–1434.
Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511–521.
Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001; 98: 10857–10862.
Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717–3721.
Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178–2189.
Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002; 92: 4015–4122.
Morgan B, Thomas AL, Devs J, Hennig J, Buchert M, Jivan A et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955–3964.
Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of the international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674.
Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005; 23: 4162–4171.
Gasparini G, Longo R, Fanelli M, Teicher BA . Combination of antiangiogenic therapy with other anticancer therapies: results, challenges and open questions. J Clin Oncol 2005; 23: 1295–1311.
Mesters RM, Padro T, Bieker R, Steins M, Kreuter M, Goner M . Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001; 98: 241–243.
Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C . Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004; 10: 3577–3585.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Roboz, G., Giles, F., List, A. et al. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 20, 952–957 (2006). https://doi.org/10.1038/sj.leu.2404213
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404213
Keywords
This article is cited by
-
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors
Investigational New Drugs (2019)
-
(Lymph)angiogenic influences on hematopoietic cells in acute myeloid leukemia
Experimental & Molecular Medicine (2014)
-
Vascular endothelial growth factor signaling in acute myeloid leukemia
Cellular and Molecular Life Sciences (2013)
-
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)
Investigational New Drugs (2013)
-
Membrane Proteins: The Key Players of a Cancer Cell
The Journal of Membrane Biology (2011)